Indications
Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.
Composition
- Active substance
- esketamine hydrochloride
- International name (INN)
- esketamine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Spravato
- Active substance
- esketamine hydrochloride
- ATC code
- N06AX27
- Group
- Nervous system
- Therapeutic area
- Depressive Disorder
- Marketing authorisation holder